Skip to main content

Regardless of Technique, Volume and Outcomes Matter

Back to Annual Report


Cedars-Sinai offers highly individualized care leveraging the full spectrum of contemporary surgical and transcatheter aortic valve therapies. Advanced surgical expertise includes aortic valve repair, valve-sparing surgery and the Ross procedure for patients with long life expectancy who wish to avoid anticoagulants.

Patients at Cedars-Sinai benefit from one of the most experienced transcatheter aortic valve replacement (TAVR) teams in the nation, providing access to cutting-edge trials and innovative new devices. With over 5,000 TAVRs performed to date, Cedars-Sinai leads the nation in volume, with some of the best outcomes to match.

Personalized care and a focus on lifelong surveillance

This high-volume, low-complication environment does not come at the expense of personalized care, research or technique innovation. Instead, it enables our interventionists and surgeons to recognize unique cases and risk factors, lead studies to advance practice and knowledge, and identify and implement ways to improve technique.

Our team approach ensures that therapy is driven by a patient’s risk profile, preferences, medical history and a thorough understanding of the heart’s condition to maximize each individual’s chance at long-term wellbeing.


A 7-year-old patient born with aortic stenosis undergoes the Ross procedure, replacing her malformed aortic valve with her own pulmonary valve, which was then replaced with a valve from a human donor. By waiting until the patient was older, the team was able to place an adult-sized pulmonary homograft, which, when it deteriorates, can be replaced through a minimally invasive approach, not a reoperation.



The JenaValve trial offers a percutaneous treatment option for extremely frail or elderly patients with severe aortic valve regurgitation. This TAVR procedure uses a stent with three eyelet clips to capture the native valve leaflets—designed specifically for the anatomy of aortic regurgitation. We are still actively recruiting participants and expect this extension of TAVR options to further improve the breadth and quality of care offered to these patients.


Cerebral Embolic Protection during Transcatheter Aortic-Valve Replacement, New England Journal of Medicine; PMID: 36121045

Association Between Transcatheter Aortic Valve Replacement for Bicuspid vs Tricuspid Aortic Stenosis and Mortality or Stroke Among Patients at Low Surgical Risk, Journal of the American Medical Association; 326:1034-1044